Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities analyst Tim Anderson sees promise for a handful of large-cap competitors. In ...

TEMPE, Ariz. — A good redemption story is enticing. With Tim Anderson, it is also complicated. The veteran is in Angels camp this spring, forced to prove himself on a minor-league contract.

In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...